JP2016522254A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522254A5
JP2016522254A5 JP2016521454A JP2016521454A JP2016522254A5 JP 2016522254 A5 JP2016522254 A5 JP 2016522254A5 JP 2016521454 A JP2016521454 A JP 2016521454A JP 2016521454 A JP2016521454 A JP 2016521454A JP 2016522254 A5 JP2016522254 A5 JP 2016522254A5
Authority
JP
Japan
Prior art keywords
compound
och
salt
pharmaceutically acceptable
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522254A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041825 external-priority patent/WO2014204730A1/en
Publication of JP2016522254A publication Critical patent/JP2016522254A/ja
Publication of JP2016522254A5 publication Critical patent/JP2016522254A5/ja
Pending legal-status Critical Current

Links

JP2016521454A 2013-06-18 2014-06-11 Ｂａｃｅ阻害剤 Pending JP2016522254A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361836175P 2013-06-18 2013-06-18
US61/836,175 2013-06-18
US201361877373P 2013-09-13 2013-09-13
US61/877,373 2013-09-13
PCT/US2014/041825 WO2014204730A1 (en) 2013-06-18 2014-06-11 Bace inhibitors

Publications (2)

Publication Number Publication Date
JP2016522254A JP2016522254A (ja) 2016-07-28
JP2016522254A5 true JP2016522254A5 (https=) 2016-09-08

Family

ID=51059662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521454A Pending JP2016522254A (ja) 2013-06-18 2014-06-11 Ｂａｃｅ阻害剤

Country Status (14)

Country Link
US (2) US9029367B2 (https=)
EP (1) EP3010925B1 (https=)
JP (1) JP2016522254A (https=)
KR (1) KR101780140B1 (https=)
CN (1) CN105324385A (https=)
AU (1) AU2014281032B2 (https=)
BR (1) BR112015029348A8 (https=)
CA (1) CA2910415C (https=)
EA (1) EA027880B1 (https=)
ES (1) ES2657905T3 (https=)
JO (1) JO3318B1 (https=)
MX (1) MX2015017156A (https=)
TW (1) TWI639607B (https=)
WO (1) WO2014204730A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
EP3334720A1 (en) 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
EP3334738A1 (en) * 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
JOP20170106A1 (ar) * 2016-05-20 2017-11-20 Lilly Co Eli مركبات تترا هيدرو فوروكسازين واستخداماتها كمثبطات bace1 انتقائية
JP6889466B2 (ja) * 2016-12-09 2021-06-18 学校法人 名城大学 アミド基を含む単離された化合物の塩、その製造方法及びこれを用いたアミド化合物の合成方法
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种（1-氟环丙基）甲胺盐酸盐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
PL2233474T3 (pl) * 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
JP5666304B2 (ja) 2008-09-30 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規な縮合アミノジヒドロチアジン誘導体
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
JPWO2011070781A1 (ja) 2009-12-09 2013-04-22 塩野義製薬株式会社 置換アミノチアジン誘導体
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
ES2624288T3 (es) 2011-01-21 2017-07-13 Eisai R&D Management Co., Ltd. Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
CA2837797A1 (en) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2603028T3 (es) 2011-11-25 2017-02-23 Adverio Pharma Gmbh Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
RU2014142545A (ru) 2012-04-27 2016-06-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения 5-(дифторметил)пиразин-2-карбоновой кислоты и промежуточного соединения при ее получении
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2016522254A5 (https=)
JP2016106149A5 (https=)
JP2016518437A5 (https=)
JP2013519675A5 (https=)
JP2019524883A5 (https=)
JP2015522589A5 (https=)
JP2016534063A5 (https=)
JP2016536286A5 (https=)
JP2015024998A5 (https=)
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2019516739A5 (https=)
JP2016525102A5 (https=)
JP2013537203A5 (https=)
JP2016528301A5 (https=)
JP2016518328A5 (https=)
RU2017105353A (ru) Соединения
JP2016539157A5 (https=)
JP2016505637A5 (https=)
JP2016510326A5 (https=)
JP2017522300A5 (https=)
JP2019505529A5 (https=)
JP2016523260A5 (https=)
JP2017511377A5 (https=)
JP2015516419A5 (https=)
JP2015521156A5 (https=)